Revolut’s $75B Valuation Signals Digital Banking’s Industrial-Scale Transformation
Digital Banking Giant’s Monumental Funding Achievement Revolut has secured a staggering $3 billion in fresh funding, catapulting its valuation to…
Digital Banking Giant’s Monumental Funding Achievement Revolut has secured a staggering $3 billion in fresh funding, catapulting its valuation to…
The DOS Gaming Renaissance Meets Modern Accessibility For technology enthusiasts and retro gaming aficionados, the challenge of preserving digital heritage…
The Engineering Marvel That Dominated OCP Summit 2025 While countless innovations competed for attention at the OCP Summit 2025, one…
The Industrialization of Personal Data Collection When you grant an app access to your contacts, you’re not just sharing phone…
Critical Input Failure Cripples Windows 11 Recovery Tools Microsoft’s latest Windows 11 25H2 October update (KB5066835) has introduced a severe…
The Luminar Power Play: More Than Meets the Eye In a stunning development that reads like corporate drama, former Luminar…
New trial results indicate Gilead Sciences’ Trodelvy significantly extends progression-free survival in advanced triple-negative breast cancer. The antibody-drug conjugate demonstrated a 38% risk reduction compared to standard chemotherapy when used as initial treatment.
Gilead Sciences’ targeted therapy Trodelvy has reportedly demonstrated substantial benefits in treating an aggressive form of breast cancer, according to recent trial results presented at the European Society for Medical Oncology meeting in Berlin. Sources indicate the drug reduced the risk of disease progression by 38% when used as initial treatment for advanced triple-negative breast cancer (TNBC) compared to standard chemotherapy.
Scientific Integrity Concerns Mount at Environmental Protection Agency Congressional leaders are demanding transparency from the Environmental Protection Agency regarding the…
Earnings Season Heats Up With Major Industrial Indicators The third-quarter earnings season has kicked into high gear, delivering stronger-than-expected results…
The Ayaneo 3 modular handheld console is set to receive significantly improved Linux support through a newly developed platform driver. This development reportedly enables enhanced hardware monitoring, power management, and modular functionality. Sources indicate the driver’s design allows for robust future support across Ayaneo’s device ecosystem.
The Ayaneo 3 modular handheld gaming console is reportedly preparing for substantially improved Linux compatibility through a newly developed platform driver, according to recent kernel development reports. Sources indicate this driver, designated ayaneo-ec, provides comprehensive hardware monitoring capabilities, sophisticated power management features, and specialized module management specifically designed for the Ayaneo 3 device.